SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Pearl Therapeutics Creates Nanogram-Dose Inhalers and Initiates a Phase 2b Study to Characterize Ultra-low Doses of Glycopyrrolate